Recurrent Ovarian Cancer Clinical Trial
— STAPOVEROfficial title:
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed beneficial in the select group of patients with a relevant predominantly active functional STP, in order to improve survival and maintain quality of life.
Status | Recruiting |
Enrollment | 148 |
Est. completion date | October 1, 2026 |
Est. primary completion date | October 1, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Female, age > 18 years - Patients with recurrent ovarian cancer who meet one of the following criteria: - Platinum-resistant disease, defined as disease recurrence or progression within six months of last platinum-based chemotherapy or; - Patient refrains from standard therapy or; - Asymptomatic patient who is not yet eligible for standard palliative chemotherapy but has an increase of CA125 tumour marker at two consecutive time points 28 days apart with a value of two times nadir above 35 U/ml. - Progressive disease after at least one prior line of systemic treatment for recurrent disease. - Radiologically evaluable disease according to RECIST 1.1 criteria (36). - Ability and willingness to obtain a tumour biopsy after the last course of standard treatment and before start of the study. - Ability and willingness to provide written and oral consent. - Able to speak and understand the Dutch language. - WHO performance status 0-II. - Adequate renal and liver function to start matched targeted therapy (according to the local clinician). - Adequate use of contraceptives in case of patients with childbearing potential. Exclusion Criteria: - Age < 18 years. - Patient is receiving any other anti-cancer therapy (e.g. cytotoxic or targeted drug or radiation) or is chemotherapy naïve. The required wash out period prior to start of matched targeted therapy is at least three weeks. - Patient is diagnosed with or treated for a second primary tumour (except non-melanoma skin tumour) one year prior to study inclusion. - Inability to obtain (sufficient) tumour material. - Previous use of the selected targeted drug as anti-cancer agent. - Physical condition WHO III-IV. - Pregnant or lactating women. - Simultaneous participation in another treatment-related clinical trial. - Patients with any other clinically significant medical condition which, in the opinion of the local clinician, makes it undesirable for the patient to participate in this study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, severe psychiatric illness, or complicated social situations. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amphia Hospital | Breda | |
Netherlands | Catharina Ziekenhuis | Eindhoven | Brabant |
Netherlands | Maastricht UMC+ | Maastricht | |
Netherlands | Radboudumc | Nijmegen | Gelderland |
Netherlands | Erasmus MC | Rotterdam | |
Netherlands | Elisabeth-Tweesteden Hospital | Tilburg |
Lead Sponsor | Collaborator |
---|---|
Gynaecologisch Oncologisch Centrum Zuid | Erasmus Medical Center, Eurofins, InnoSIGN, Maastricht University Medical Center, Radboud University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival on matched targeted therapy determined by STP-activity (PFS2) in comparison to the PFS recorded on the therapy administered immediately prior to enrolment (PFS1). | PFS on matched targeted therapy (PFS2) is defined as the time from start of matched targeted therapy to disease progression, defined by RECIST 1.1 criteria, or death from any cause. PFS on prior therapy (PFS1) is defined as the time from start of the prior treatment to disease progression defined by RECIST 1.1 criteria | From baseline until the date of documented disease progression or 12 months after the start of targeted therapy. | |
Secondary | Proportion of patients with an actionable active pathway for which targeted therapy is recommended in relation to the number of patients who underwent a biopsy. | From date of biopsy until the date of the result from Multi-disciplinary Tumor Board Meeting, up 14 days after biopsy date. | ||
Secondary | Proportion of patients who receive matched targeted therapy in relation to the number of patients included in each study arm. | Proportion of patients included in arm A, B, C, D. | From start date matched targeted therapy until the end of the study enrollment, up to 36 months. | |
Secondary | Best overall response defined by RECIST 1.1 criteria based on radiological imaging. | From baseline, radiological evaluation every 12 weeks after the start of targeted therapy until the date of documented disease progression or death, whichever comes first, assessed up to 12 months. | ||
Secondary | One-year survival | One-year survival is defined as the time from start matched targeted therapy till death or the end of the one-year follow-up period. | From start date of targeted therapy until date of death or one year follow-up, whichever comes first. | |
Secondary | Overall survival | Defined as the time from start matched targeted therapy till death. | From start date of targeted therapy until the date of death, assessed up to 36 months. | |
Secondary | Predictive value of STA-analysis results on matched targeted therapy response. | From start date targeted therapy until response evaluation at 12 weeks after start of targeted therapy. | ||
Secondary | Side effects | Assessed according to the PRO-CTCAE and NCI CTCAE 5.0 | From start date of targeted therapy after two weeks, every 12 weeks from targeted therapy start date, until 12 weeks after end of treatment. | |
Secondary | Health Related Quality of Life | HRQoL is assessed using standardized questionnaires from the EORTC QLQ-C30 and QLQ-OV28. | From baseline, every 12 weeks after start date of treatment until 12 weeks after end of treatment. | |
Secondary | Cost-effectiveness | Standardized EuroQol 5D (EQ-5D-5L) questionnaire is used to calculated the cost-effectiveness. | From baseline, every 12 weeks after start date of targeted therapy until 12 weeks after end of treatment. | |
Secondary | Change in pathway activity score after disease progression compared to pathway activity score before start of matched therapy. | If pathway activity scores are available from a second (voluntary) biopsy for after treatment has ended and before standard (palliative) treatment has started, change in pathway scores are assessed. | From date of biopsy until 4 weeks after date of documented progression of disease. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02195973 -
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05270720 -
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06070285 -
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
|
||
Completed |
NCT02303912 -
Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01802749 -
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
|
Phase 3 | |
Completed |
NCT02788708 -
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03564340 -
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05610735 -
Combination Therapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02083536 -
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
|
Phase 1 | |
Completed |
NCT03430518 -
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03618706 -
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05311579 -
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01851746 -
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT06107868 -
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
|
Phase 1 | |
Recruiting |
NCT06308406 -
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06365853 -
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
|
Phase 2 | |
Completed |
NCT04718740 -
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05335993 -
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
|
Phase 2 | |
Completed |
NCT01381861 -
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05126342 -
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
|
Phase 2 |